Metabolomics biomarkers for precision psychiatry
Frontiers in Psychiatry · 13.02.2026 · 17
DOI: 10.3389/fpsyt.2026.1736206 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Psychiatry, online erschienen am 13.02.2026. Verfasst von Daniele Cavaleri und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell’Università e della Ricerca.
Abstract (Originalsprache)
Mental disorders remain diagnosed primarily through symptom-based classification systems that overlook biological heterogeneity, preventing the identification of mechanistically distinct patient subgroups and precluding pathophysiology-guided treatment selection. Metabolomics offers a promising pathway towards precision psychiatry by capturing dynamic biochemical readouts at the functional endpoint of the omics cascade, integrating genetic, environmental, and pharmacological influences on cellular metabolism. Over the past 15 years, untargeted and targeted metabolomics studies using nuclear magnetic resonance spectroscopy and mass spectrometry have identified consistent patterns of metabolic dysregulation across psychiatric disorders, particularly involving amino acid metabolism, lipid signaling, energy homeostasis, and oxidative stress pathways. Schizophrenia presents disruptions in arginine and proline metabolism, glutathione metabolism, and energy-related processes. Bipolar disorder shows perturbations in branched-chain and aromatic amino acids, kynurenine pathway, and tricarboxylic acid cycle dysfunction with phase-specific metabolic signatures. Major depressive disorder exhibits widespread alterations in amino acid turnover, bioenergetic processes, membrane lipid homeostasis, and glutamate-GABA cycling, with treatment-responsive metabolic changes. Despite these advances, substantial challenges remain: heterogeneous findings with disorder overlap, limited replication cohorts, predominance of cross-sectional designs, confounding by medication and lifestyle factors, pre-analytical variability, and high-dimensional data complexity. Future research requires harmonized multi-site protocols, longitudinal validation studies, multi-platform analytical approaches, integration with genomics, proteomics, and digital phenotyping, and implementation of artificial intelligence frameworks to enhance phenotype discrimination and predictive accuracy. In this mini-review, we provide an overview of current methodologies, major findings, strengths, challenges, and emerging directions in psychiatric metabolomics, with the goal of facilitating the translation of metabolomic insights into clinically applicable, personalized psychiatric treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
- Department of Health Sciences, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.
- Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
Förderung
- Ministero dell’Università e della Ricerca
Zitieren
APA
Cavaleri, D., Bassetti, C., Cucchi, G., De Fazio, P., de Filippis, R., Albert, U., Pellegrini, L., Carrà, G., & Bartoli, F. (2026). Metabolomics biomarkers for precision psychiatry. Frontiers in Psychiatry, 17. https://doi.org/10.3389/fpsyt.2026.1736206
Vancouver
Cavaleri D, Bassetti C, Cucchi G, De Fazio P, de Filippis R, Albert U, et al. Metabolomics biomarkers for precision psychiatry. Frontiers in Psychiatry. 2026;17. doi:10.3389/fpsyt.2026.1736206
BibTeX
@article{Cavaleri2026,
author = {Cavaleri, Daniele and Bassetti, Carlo and Cucchi, Giorgio and De Fazio, Pasquale and de Filippis, Renato and Albert, Umberto and Pellegrini, Luca and Carrà, Giuseppe and Bartoli, Francesco},
title = {Metabolomics biomarkers for precision psychiatry},
journal = {Frontiers in Psychiatry},
year = {2026},
volume = {17},
doi = {10.3389/fpsyt.2026.1736206}
}
EUVIMED